Blood Screening

Blood Screening Market Outlook

The global blood screening market is projected to reach approximately USD 4.8 billion by 2035, with a compound annual growth rate (CAGR) of around 7.5% during the forecast period from 2025 to 2035. The growth of this market can largely be attributed to the increasing prevalence of blood-borne diseases, rising awareness about blood safety, and the continuous advancements in blood screening technologies. Additionally, the growing emphasis on transfusion safety and the rise in health check-ups among the population are driving the demand for effective blood screening solutions. Governments and health organizations are also investing in blood screening programs, which enhance the overall market growth. Furthermore, innovations in laboratory diagnostics and the emergence of automated blood screening systems are expected to propel the market significantly.

Growth Factor of the Market

The blood screening market is experiencing significant growth primarily due to the increasing incidence of infectious diseases, which necessitates the rigorous screening of blood donations to ensure safety. With the rise in conditions such as HIV, Hepatitis B, and Hepatitis C, healthcare institutions are focusing on improving their screening processes to mitigate the risk of transmission through blood transfusions. The technological advancements in screening methods, such as the development of high-throughput screening techniques and molecular diagnostics, are further expected to boost market growth. Moreover, an aging population with higher susceptibility to diseases and an increase in surgical procedures are contributing factors leading to the heightened demand for blood screening services. The global push for improving transfusion safety standards and a focus on patient safety in emerging economies also stand as vital growth factors in this market.

Key Highlights of the Market

• The blood screening market is expected to grow at a CAGR of 7.5% from 2025 to 2035.
• Increasing prevalence of blood-borne diseases is driving the demand for blood screening.
• Technological advancements in screening methods enhance efficiency and accuracy.
• Rising health awareness and safety regulations are influencing market growth.
• Emerging economies are investing significantly in healthcare infrastructure, boosting demand.

By Product Type

Instruments:

The instruments segment remains a core component of the blood screening market, encompassing a wide range of devices designed for analyzing blood samples. These instruments include automated analyzers that can perform various tests simultaneously, enhancing efficiency in laboratories. The demand for advanced instruments is driven by their ability to deliver rapid and accurate results, which is essential for timely diagnosis and treatment of various conditions. With the introduction of user-friendly interfaces and integration with laboratory information systems, these instruments are becoming indispensable in healthcare settings. Additionally, innovations such as point-of-care testing devices are gaining traction, allowing for immediate results in emergency situations, thus further propelling the segment's growth.

Reagents & Kits:

The reagents and kits segment is vital for the blood screening market as it includes the essential products necessary for performing tests. These reagents and kits are designed for various blood tests, ranging from routine screenings to specialized testing for infectious diseases. The growing emphasis on accurate blood testing has led to significant advancements in reagent formulations, improving sensitivity and specificity. With an increasing focus on personalized medicine, there is a rising demand for customized kits tailored for specific patient populations, which is expected to enhance market growth. Additionally, the convenience offered by ready-to-use kits is appealing to diagnostic centers, thereby driving the segment's development.

Services:

The services segment in the blood screening market encompasses laboratory services, consultation, and support services related to blood testing. As healthcare facilities continuously strive to enhance patient care and safety, the demand for specialized services has surged. This includes the provision of comprehensive blood screening packages that combine various tests for thorough examination. The trend towards outsourcing laboratory services to specialized providers is also gaining momentum, allowing healthcare facilities to focus on core activities while ensuring high-quality testing. Additionally, the growth of telemedicine and remote diagnostics is expected to shape the services segment, making blood screening more accessible and efficient.

By Technology

Enzyme-Linked Immunosorbent Assay (ELISA):

The enzyme-linked immunosorbent assay (ELISA) technology is a cornerstone of the blood screening market due to its high specificity and sensitivity in detecting various pathogens and antibodies. This technology is widely used for screening blood donations for infectious agents such as HIV and Hepatitis viruses. The ease of use of ELISA kits, along with their ability to process large volumes of samples simultaneously, makes them a preferred choice in laboratories. Furthermore, continuous improvements in assay formats and the development of multiplex ELISA systems are enhancing the technology's applicability across various disease states, thereby driving market growth.

Polymerase Chain Reaction (PCR):

Polymerase chain reaction (PCR) technology has revolutionized blood screening by enabling rapid and accurate detection of nucleic acids from pathogens. PCR is particularly effective in identifying infections that might not be detectable through traditional methods, making it invaluable in blood screening. The ability to process samples quickly allows for timely diagnosis and treatment, which is critical in managing infectious diseases. The growing inclination towards molecular diagnostics and the need for precise testing have significantly propelled the adoption of PCR in blood screening procedures. Additionally, advancements in real-time PCR and quantitative PCR are further enhancing the capabilities of this technology in various clinical settings.

Next-Generation Sequencing (NGS):

Next-generation sequencing (NGS) is an innovative technology that is increasingly being applied in the blood screening market for comprehensive genomic analysis. NGS allows for the simultaneous sequencing of multiple DNA or RNA targets, enabling the detection of a wide array of pathogens in a single test. This technology is particularly beneficial in screening for pathogens that are hard to identify with conventional methods. The ability to provide detailed insights into the genetic material of microorganisms enhances the understanding of infections and improves patient management. The growing demand for personalized medicine and targeted therapies is further driving the adoption of NGS in blood screening.

Flow Cytometry:

Flow cytometry is another key technology utilized in the blood screening market, particularly in the analysis of blood cells and detection of specific cell populations. This technology allows for rapid quantification and characterization of cells, making it essential for diagnosing blood disorders and infections. Flow cytometry's ability to analyze multiple parameters simultaneously provides a comprehensive assessment of blood samples, enhancing the accuracy of diagnostics. The increasing prevalence of hematological disorders and the need for effective monitoring of blood components are fueling the growth of flow cytometry applications in blood screening.

Others:

In addition to the aforementioned technologies, various other methods are also employed in the blood screening market, including immunofluorescence, mass spectrometry, and microfluidics. These technologies are being integrated into laboratory practices to improve the efficiency and accuracy of blood testing. The development of microfluidic devices, for instance, is enabling rapid and portable blood analysis, which can benefit point-of-care testing scenarios. The diversity of technologies available for blood screening allows for tailored approaches depending on the specific needs of healthcare providers and patients, further enhancing the market's growth potential.

By Linked Immunosorbent Assay

Direct ELISA:

Direct ELISA is a widely used method for detecting antigens in blood samples. This technique involves coating a microplate with the sample, allowing any present antigens to adhere to the plate, followed by the addition of a labeled antibody specific to the target antigen. The simplicity and speed of the direct ELISA method make it a popular choice in clinical laboratories for routine blood screening. Its application in detecting diseases such as HIV and Hepatitis has significantly contributed to ensuring blood safety, thereby enhancing public health. The increasing adoption of direct ELISA in various diagnostic settings is anticipated to drive its market growth.

Indirect ELISA:

Indirect ELISA provides an additional layer of sensitivity and specificity in the detection of antibodies against a specific antigen. This method involves the use of two antibodies: one that binds to the antigen and another labeled antibody that binds to the first antibody. This multi-step process allows for the amplification of the signal, making it easier to detect low concentrations of antibodies in blood samples. The versatility of indirect ELISA makes it applicable in various fields, including autoimmune disease diagnostics and infectious disease monitoring, thus contributing to its expanding market presence.

Sandwich ELISA:

Sandwich ELISA is particularly effective for measuring the concentration of antigens in blood samples, benefiting from its ability to capture the target antigen between two antibodies. This method is highly specific and is used extensively in research and diagnostic applications to detect biomarkers associated with diseases. The capacity of sandwich ELISA to quantify biomolecules with precision makes it invaluable for both clinical diagnostics and therapeutic monitoring. The growing focus on biomarker discovery in medicine is expected to enhance the demand for sandwich ELISA in blood screening applications.

By Polymerase Chain Reaction

Conventional PCR:

Conventional PCR remains a fundamental method in molecular diagnostics, especially in the context of blood screening for infectious diseases. This technique amplifies specific DNA sequences, allowing for the detection of pathogens in blood samples. Its effectiveness in identifying infections such as HIV and Hepatitis C is well-documented, making it a staple in diagnostic laboratories. While its throughput may not match that of newer technologies, conventional PCR's reliability and cost-effectiveness ensure its continued relevance in the blood screening market. The ongoing advancements in PCR techniques are likely to enhance its efficiency even further.

Real-Time PCR:

Real-time PCR has transformed blood screening by providing rapid and quantitative results, enabling healthcare providers to make timely decisions regarding patient management. This technology allows for the monitoring of the amplification process in real-time, delivering results in a fraction of the time compared to conventional PCR methods. The enhanced sensitivity and specificity of real-time PCR have established it as a preferred choice in clinical applications, particularly in detecting viral loads in patients. As the demand for fast and accurate diagnostics grows, real-time PCR is poised for substantial market expansion.

By Generation Sequencing

Sanger Sequencing:

Sanger sequencing, the first-generation sequencing method, remains relevant in specific applications within the blood screening market, particularly for confirming the presence of specific pathogens or mutations in blood samples. The reliability and accuracy of Sanger sequencing make it a valuable tool for validating findings from other screening methods. Its use in clinical settings for targeted diagnostics ensures that Sanger sequencing continues to play a role in comprehensive blood screening protocols. The market for Sanger sequencing is expected to persist, supported by ongoing research and its utility in personalized medicine.

Next-Generation Sequencing (NGS):

Next-generation sequencing (NGS) is at the forefront of innovation in blood screening, allowing for the high-throughput analysis of genetic material. This technology enables the simultaneous sequencing of multiple genes, providing insights into a wide range of diseases, including genetic disorders and infections. The comprehensive nature of NGS allows for detailed pathogen profiling, which is particularly beneficial in tailoring treatment plans for patients. With the increasing adoption of NGS in clinical practice and research, this segment is anticipated to witness significant growth as healthcare continues to evolve towards precision medicine.

By Test Type

Routine Blood Tests:

Routine blood tests are essential components of standard healthcare practice, serving as preliminary screenings for various health conditions. These tests often include complete blood counts, metabolic panels, and lipid profiles that provide comprehensive insights into a patient's health status. The increasing prevalence of chronic diseases, such as diabetes and cardiovascular conditions, has heightened the demand for routine blood testing. As healthcare systems emphasize preventive care and early diagnosis, the routine blood tests segment is expected to continue its growth trajectory, supported by advancements in testing technologies that improve accuracy and efficiency.

Specialty Blood Tests:

Specialty blood tests focus on identifying specific diseases or conditions that may not be detected through routine screening. These tests often require advanced technologies and specialized reagents, making them crucial for diagnosing complex diseases such as autoimmune disorders and certain cancers. The growing awareness of the importance of early detection in managing health conditions has led to increased adoption of specialty blood tests in clinical settings. As research continues to uncover novel biomarkers for various diseases, the specialty blood tests segment is anticipated to expand, driven by the need for targeted diagnostics.

By End User

Hospitals:

Hospitals constitute a significant end user segment in the blood screening market, as they are key facilities for diagnosing and treating patients. These institutions rely heavily on accurate blood screening to ensure safe transfusions and effective disease management. The increasing number of surgical procedures and the prevalence of blood-borne diseases are driving hospitals to adopt advanced blood screening technologies. Moreover, hospitals are investing in automated laboratory systems to streamline their testing processes and improve turnaround times. As patient care continues to evolve, the demand for comprehensive blood screening services in hospitals is expected to grow.

Diagnostic Centers:

Diagnostic centers play a pivotal role in the blood screening market, providing specialized testing services to patients. These centers often offer a wide range of tests, including routine and specialty blood screenings, catering to the needs of both individuals and healthcare providers. The convenience and accessibility of diagnostic centers are driving patient preferences for blood testing services, particularly for outpatient procedures. The increasing focus on preventive healthcare and wellness check-ups is further boosting the demand for diagnostic centers, making them vital players in the blood screening landscape. The integration of advanced technologies in these centers is expected to enhance testing capabilities and service offerings.

Blood Banks:

Blood banks are critical entities within the blood screening market, responsible for the collection, testing, and storage of blood donations. The rigorous screening of donated blood for infectious diseases is essential to ensure transfusion safety and protect recipients. With the rising demand for blood products due to surgical procedures and trauma care, blood banks are increasingly investing in advanced screening technologies. This segment is witnessing growth as blood banks enhance their testing protocols to meet regulatory standards and improve patient outcomes. The emphasis on volunteer blood donations and the need for comprehensive screening are expected to drive the expansion of blood banks in the coming years.

By Region

The blood screening market exhibits notable regional variations, influenced by factors such as healthcare infrastructure, disease prevalence, and technological adoption. North America currently dominates the market, accounting for over 40% of the global revenue share. The region's advanced healthcare infrastructure, coupled with a high prevalence of chronic diseases and blood-borne infections, fuels demand for effective blood screening solutions. The United States, in particular, is witnessing significant investments in blood safety initiatives, further bolstering market growth. Simultaneously, the Asia Pacific region is projected to exhibit the highest CAGR of around 8.5% during the forecast period. The rising healthcare expenditure, increasing awareness of blood donation safety, and the expansion of healthcare facilities in nations such as India and China are key drivers of this growth.

Europe is also a significant player in the blood screening market, contributing approximately 25% to the global market share. The increasing emphasis on transfusion safety and the implementation of stringent regulations regarding blood testing are driving the demand for blood screening technologies in the region. Countries like Germany and France are investing in advanced diagnostic methods, leading to increased adoption of blood screening solutions. The Latin America market, while smaller in comparison, is witnessing gradual growth due to improving healthcare access and rising awareness of infectious diseases, and the Middle East & Africa is gradually embracing advanced blood screening technologies, albeit at a slower pace due to varying healthcare infrastructure and resource limitations.

Opportunities

The blood screening market presents numerous opportunities for growth, particularly in developing regions where healthcare infrastructure is improving. As countries invest in better healthcare systems and increase access to medical services, the demand for reliable blood screening solutions is expected to rise. This is particularly evident in regions like Asia Pacific and Latin America, where initiatives to enhance disease detection and prevention are gaining momentum. Additionally, the increasing prevalence of chronic diseases and the need for regular health check-ups are prompting healthcare providers to implement comprehensive blood screening programs. Companies that focus on developing affordable and accessible blood screening technologies will likely find substantial market opportunities in these regions.

Furthermore, technological advancements such as automation in laboratories and the development of portable testing devices are set to revolutionize the blood screening landscape. The integration of artificial intelligence and machine learning in diagnostic processes is paving the way for enhanced accuracy and efficiency in blood screening tests. Companies that invest in research and development to innovate new testing methodologies and improve existing technologies can capitalize on the growing demand for advanced blood screening solutions. Collaborations with healthcare institutions and participation in public health initiatives will also present lucrative opportunities for stakeholders in this evolving market.

Threats

The blood screening market faces several threats that could hinder its growth trajectory. One of the primary concerns is the increasing prevalence of counterfeit diagnostic products that pose significant risks to patient safety. The presence of substandard testing kits and reagents can lead to inaccurate results, undermining the credibility of blood screening processes. Additionally, the growing incidence of healthcare-associated infections and the emergence of antibiotic-resistant pathogens highlight the need for continuous innovation in testing methodologies. Regulatory challenges regarding the approval and commercialization of new blood screening technologies can also pose significant barriers to market entry, particularly for smaller companies with limited resources.

On another note, the high costs associated with advanced blood screening technologies may limit their adoption in resource-constrained settings. Smaller diagnostic centers and healthcare facilities may struggle to invest in expensive equipment and reagents, leading to disparities in the availability of quality blood screening services. Furthermore, the global impact of economic downturns and fluctuations in healthcare funding can adversely affect market growth. Stakeholders must navigate these challenges while remaining focused on maintaining quality and safety in blood screening practices to sustain market momentum.

Competitor Outlook

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Ortho Clinical Diagnostics
• bioMérieux
• Danaher Corporation
• BD (Becton, Dickinson and Company)
• Qiagen N.V.
• PerkinElmer, Inc.
• Hologic, Inc.
• GenMark Diagnostics
• Grifols S.A.
• Sysmex Corporation
• Abcam plc

The competitive landscape of the blood screening market is characterized by the presence of several key players that are continually innovating to gain market share. Prominent companies such as Roche Diagnostics and Abbott Laboratories are at the forefront, offering a diverse range of advanced blood testing solutions. These companies leverage their extensive research and development capabilities to introduce cutting-edge technologies that enhance the efficiency and accuracy of blood screening processes. Additionally, strategic partnerships and collaborations among industry players are common, aimed at expanding product portfolios and enhancing market reach. For instance, alliances between healthcare providers and diagnostic companies facilitate the integration of advanced testing technologies into clinical practices, further contributing to market growth.

Another notable aspect of the competitive landscape is the increasing focus on mergers and acquisitions as companies seek to strengthen their market position. Major players such as Siemens Healthineers and Thermo Fisher Scientific have actively pursued acquisitions to enhance their technological capabilities and expand their offerings in the blood screening space. These strategic moves not only broaden their product range but also allow them to tap into new markets and customer segments. Furthermore, smaller companies specializing in niche applications are making their mark by introducing innovative solutions that cater to specific testing needs, thus intensifying competition within the market.

Key players in the blood screening market, such as bioMérieux and Danaher Corporation, are also investing significantly in research and development efforts to stay ahead of emerging trends. These companies are focusing on developing next-generation technologies, such as molecular diagnostics and point-of-care testing solutions, to meet the evolving demands of healthcare providers. As patient-centric care becomes more prevalent, the emphasis on quick and accurate results drives these companies to continuously innovate their product offerings. Furthermore, as regulatory bodies enforce stricter testing standards, companies that demonstrate quality and compliance will be better positioned to capture a larger share of the blood screening market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Abcam plc
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Qiagen N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Grifols S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Hologic, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Diagnostics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 bioMérieux
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Sysmex Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Danaher Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GenMark Diagnostics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Siemens Healthineers
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Thermo Fisher Scientific
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Ortho Clinical Diagnostics
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 BD (Becton, Dickinson and Company)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Blood Screening Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Diagnostic Centers
    • 6.1.3 Blood Banks
    • 6.1.4 Others
  • 6.2 Blood Screening Market, By Test Type
    • 6.2.1 Routine Blood Tests
    • 6.2.2 Specialty Blood Tests
  • 6.3 Blood Screening Market, By Technology
    • 6.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
    • 6.3.2 Polymerase Chain Reaction (PCR)
    • 6.3.3 Next-Generation Sequencing (NGS)
    • 6.3.4 Flow Cytometry
    • 6.3.5 Others
  • 6.4 Blood Screening Market, By Product Type
    • 6.4.1 Instruments
    • 6.4.2 Reagents & Kits
    • 6.4.3 Services

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Blood Screening Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Blood Screening market is categorized based on

By Product Type

• Instruments
• Reagents & Kits
• Services

By Technology

• Enzyme-Linked Immunosorbent Assay (ELISA)
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS)
• Flow Cytometry
• Others

By Test Type

• Routine Blood Tests
• Specialty Blood Tests

By End User

• Hospitals
• Diagnostic Centers
• Blood Banks
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Roche Diagnostics
• Abbott Laboratories
• Thermo Fisher Scientific
• Siemens Healthineers
• Ortho Clinical Diagnostics
• bioMérieux
• Danaher Corporation
• BD (Becton, Dickinson and Company)
• Qiagen N.V.
• PerkinElmer, Inc.
• Hologic, Inc.
• GenMark Diagnostics
• Grifols S.A.
• Sysmex Corporation
• Abcam plc